ArticleMedicine2026
A cross-sectional study on the growth and development of preterm infants during the first year of life in Tibet's Lhasa Region.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Limited data exist on early growth and hematological parameters of preterm infants in high-altitude regions. This study was aimed to examine the growth and neurodevelopmental outcomes and the incidence of anemia and vitamin D deficiency (VDD) during the first year of life in preterm infants residing in Tibet's Lhasa Region. This cross‑sectional study enrolled 228 preterm infants (including 98 small‑for‑gestational‑age [SGA] and 38 very preterm [VP] infants). At each follow‑up visit, 151, 117, 125, and 98 infants completed assessments at corrected ages (CA) of 1, 3, 6, and 12 months, respectively. Anthropometric measurements measured by trained health professionals at CA of 1, 3, 6, and 12 months. Neurodevelopment was assessed using the Infant Neurological Motor Assessment (20-item version, N20) at CA of 1, 3, and 6 months, the Alberta Infant Motor Scale at CA of 3 and 6 months, and the Developmental Screening Test at CA of 12 months. Venous blood samples were collected at CA of 6 and 12 months to determine hemoglobin (Hb, g/L) and serum 25-hydroxyvitamin D (ng/mL) levels. Anemia was defined as Hb < 137 g/L, and VDD was defined as serum 25-hydroxyvitamin D < 20 ng/mL. Preterm SGA infants showed significantly lower Z-scores for height, weight, and head circumference, with higher rates of underweight, stunting, and microcephaly. Similarly, VP infants displayed analogous patterns of compromised physical growth to preterm SGA infants. Furthermore, the SGA group exhibited a higher prevalence of development delay. Both SGA and VP birth were independently identified as significant risk factors for developmental delay. Anemia prevalence was 62.5% (35/56) at 6 months and 48.6% (35/72) at 12 months, while VDD rates decreased from 5% (2/40) to 3.4% (2/59) over the same period. In this high-altitude study, preterm infants as a group exhibited suboptimal growth indicators, a high prevalence of developmental delay, and a significant burden of anemia during their first year. These challenges were most severe in those born SGA or VP. Infants who were neither SGA nor VP showed better growth and neurodevelopmental outcomes. These findings advocate for enhanced surveillance and tailored interventions for all preterm infants, particularly high-risk subgroups, in high-altitude settings.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.